Table 2.
Odds ratios of dementia among older adults with depression using selective serotonin reuptake inhibitors (SSRIs)/serotonin and norepinephrine reuptake inhibitors (SNRIs) compared to those receiving psychotherapy
| Crude incidence (%) | OR (95% CI) | Adjusted marginal effect (%) | |||
|---|---|---|---|---|---|
| SSRI/SNRI | Psychotherapy | Crude | Adjusted | ||
| Main analysis: SSRI/SNRI vs. psychotherapy (n = 2,710) |
16.1 | 12.7 | 1.46 (0.97–2.20) | 1.39 (1.21–1.59)* | 32.6* |
| Subgroup analysis stratified by | |||||
| Age | |||||
| < 65 years (n = 1,697) | 15.3 | 12.3 | 1.18 (0.75–1.87) | 1.38 (1.17–1.64)* | 32.4* |
| ≥ 65 years (n = 1,013) | 17.3 | 13.9 | 2.38 (1.05–5.41) | 1.52 (1.21–1.91)* | 41.8* |
| Sex | |||||
| Male (n = 835) | 16.5 | 11.6 | 1.42 (0.81–2.50) | 1.37 (1.08–1.74)* | 31.4* |
| Female (n = 1,875) | 15.9 | 13.4 | 1.52 (0.91–2.54) | 1.40 (1.19–1.65)* | 33.4* |
| Race | |||||
| White (n = 1,994) | 14.0 | 9.0 | 1.81 (1.00–3.27) | 1.60 (1.36–1.87)* | 46.8* |
| Black (n = 203) | 21.1 | 16.7 | 1.04 (0.62–1.74) | 0.75 (0.55–1.02) | −28.6 |
| PHQ-2 score | |||||
| 0–2 (n = 1,918) | 15.6 | 12.1 | 1.39 (0.83–2.33) | 1.49 (1.28–1.75)* | 40.1* |
| 3–6 (n = 506) | 19.3 | 15.4 | 1.75 (0.96–3.20) | 1.08 (0.82–1.41) | 7.2 |
| Concomitant antidepressants other than SSRI/SNRI | |||||
| Yes (n = 58) | 28.3 | 16.7 | 7.67 (6.93–8.49) | 0.75 (0.34–1.66) | −28.3 |
| No (n = 2,652) | 15.8 | 12.5 | 1.41 (0.94–2.13) | 1.40 (1.22–1.61)* | 33.7* |
| Underlying cognitive impairment | |||||
| Yes (n = 541) | 22.8 | 17.8 | 1.49 (0.99–2.24) | 0.84 (0.66–1.05) | −17.9 |
| No (n = 2,169) | 14.5 | 10.6 | 1.51 (0.89–2.57) | 0.78 (1.50–2.12)* | 57.7* |
Abbreviations: SSRI, selective serotonin reuptake inhibitors; SNRI, serotonin and norepinephrine reuptake inhibitors; RRD, relative risk difference; OR, odds ratio; CI, confidence interval
*
An asterisk means that the result is significant